The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2017 | Which treatments are currently available for relapsed and refractory myeloma treatment?
Meletios Dimopoulos, MD, from the Athens School of Medicine, Athens, Greece, gives an overview of the treatments currently available for relapsed and refractory myeloma treatment at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. He highlights important factors in choosing a treatment, including the type of relapse a patient is having, prior myeloma therapy, and accumulated toxicities. Prof. Dimopoulos also speaks about the influence of the cytogenetic profile of the patient, whether a patient has extramedullary disease and their renal function on treatment choice.
